While science was at the heart of the patent argument Amgen Inc. made Tuesday before the U.S. Court of Appeals for the Federal Circuit, emotion and public policy could determine whether the court lifts a permanent injunction against the U.S. marketing of Sanofi SA and Regeneron Pharmaceuticals Inc.'s Praluent (alirocumab).